Uric Acid and Treatment With Empagliflozin in Heart Failure with Preserved Ejection Fraction (HFpEF): the EMPEROR-Preserved Trial

被引：0
|
作者：
Green, Jennifer [1 ,2 ]
机构：
[1] Duke Univ, Dept Med, Duke Clin Res Inst, Med Ctr, Durham, NC USA
[2] Duke Univ, Med Ctr, Div Endocrinol, Durham, NC USA
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2023年 / 142卷
关键词：
empagliflozin; heart failure; HFpEF; hyperuricemia; SGLT2;
D O I：
10.1016/j.metabol.2023.155468
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0074
引用
收藏
页码：S25 / S25
页数：1
相关论文
共 50 条
  • [31] Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial
    Fauchier, Laurent
    Lamblin, Nicolas
    Tardu, Jean
    Bellier, Lucile
    Groyer, Harinala
    Ittah, Deborah
    Chollet, Julien
    Linden, Stephan
    Levy, Pierre
    [J]. PHARMACOECONOMICS-OPEN, 2024, 8 (01) : 19 - 30
  • [32] Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial
    Laurent Fauchier
    Nicolas Lamblin
    Jean Tardu
    Lucile Bellier
    Harinala Groyer
    Deborah Ittah
    Julien Chollet
    Stephan Linden
    Pierre Levy
    [J]. PharmacoEconomics - Open, 2024, 8 : 19 - 30
  • [33] Plain language summary of the EMPEROR-Preserved study looking at the effect of empagliflozin in patients with heart failure with preserved ejection fraction, with and without diabetes
    Butler, Javed
    Filippatos, Gerasimos
    [J]. FUTURE CARDIOLOGY, 2023, 19 (15) : 723 - 733
  • [34] Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
    Stefan D. Anker
    Javed Butler
    Muhammad Shariq Usman
    Gerasimos Filippatos
    João Pedro Ferreira
    Edimar Bocchi
    Michael Böhm
    Hans Pieter Brunner-La Rocca
    Dong-Ju Choi
    Vijay Chopra
    Eduardo Chuquiure
    Nadia Giannetti
    Juan Esteban Gomez-Mesa
    Stefan Janssens
    James L. Januzzi
    José R. González-Juanatey
    Bela Merkely
    Stephen J. Nicholls
    Sergio V. Perrone
    Ileana L. Piña
    Piotr Ponikowski
    Michele Senni
    David Sim
    Jindrich Spinar
    Iain Squire
    Stefano Taddei
    Hiroyuki Tsutsui
    Subodh Verma
    Dragos Vinereanu
    Jian Zhang
    Tomoko Iwata
    Janet M. Schnee
    Martina Brueckmann
    Stuart J. Pocock
    Faiez Zannad
    [J]. Nature Medicine, 2022, 28 : 2512 - 2520
  • [35] Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
    Anker, Stefan D.
    Butler, Javed
    Usman, Muhammad Shariq
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Bocchi, Edimar
    Bohm, Michael
    Brunner-La Rocca, Hans Pieter
    Choi, Dong-Ju
    Chopra, Vijay
    Chuquiure, Eduardo
    Giannetti, Nadia
    Gomez-Mesa, Juan Esteban
    Janssens, Stefan
    Januzzi, James L.
    Gonzalez-Juanatey, Jose R.
    Merkely, Bela
    Nicholls, Stephen J.
    Perrone, Sergio V.
    Pina, Ileana L.
    Ponikowski, Piotr
    Senni, Michele
    Sim, David
    Spinar, Jindrich
    Squire, Iain
    Taddei, Stefano
    Tsutsui, Hiroyuki
    Verma, Subodh
    Vinereanu, Dragos
    Zhang, Jian
    Iwata, Tomoko
    Schnee, Janet M.
    Brueckmann, Martina
    Pocock, Stuart J.
    Zannad, Faiez
    [J]. NATURE MEDICINE, 2022, 28 (12) : 2512 - +
  • [36] Heart failure with preserved ejection fraction (HFpEF)
    Maeder, Micha T.
    Buser, Marc
    Brenner, Roman
    Rickli, Hans
    [J]. THERAPEUTISCHE UMSCHAU, 2018, 75 (03) : 161 - 169
  • [37] Design and rationale of the EMPEROR trials of empagliflozin 10mg once daily in patients with chronic heart failure with reduced ejection fraction (EMPEROR-Reduced) or preserved ejection fraction (EMPEROR-Preserved)
    Anker, S. D.
    Zannad, F.
    Butler, J.
    Filippatos, G.
    Schnee, J.
    Zeller, C.
    Pocock, S.
    George, J. T.
    Brueckmann, M.
    Packer, M.
    [J]. DIABETIC MEDICINE, 2019, 36 : 47 - 47
  • [38] Empagliflozin in Heart Failure with a Preserved Ejection Fraction
    不详
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (21):
  • [39] Empagliflozin in Heart Failure with a Preserved Ejection Fraction
    Anker, Stefan D.
    Butler, Javed
    Filippatos, Gerasimos
    Ferreira, Joao P.
    Bocchi, Edimar
    Boehm, Michael
    Brunner-La Rocca, Hans-Peter
    Choi, Dong-Ju
    Chopra, Vijay
    Chuquiure-Valenzuela, Eduardo
    Giannetti, Nadia
    Gomez-Mesa, Juan Esteban
    Janssens, Stefan
    Januzzi, James L.
    Gonzalez-Juanatey, Jose R.
    Merkely, Bela
    Nicholls, Stephen J.
    Perrone, Sergio V.
    Pina, Ileana L.
    Ponikowski, Piotr
    Senni, Michele
    Sim, David
    Spinar, Jindrich
    Squire, Iain
    Taddei, Stefano
    Tsutsui, Hiroyuki
    Verma, Subodh
    Vinereanu, Dragos
    Zhang, Jian
    Carson, Peter
    Lam, Carolyn Su Ping
    Marx, Nikolaus
    Zeller, Cordula
    Sattar, Naveed
    Jamal, Waheed
    Schnaidt, Sven
    Schnee, Janet M.
    Brueckmann, Martina
    Pocock, Stuart J.
    Zannad, Faiez
    Packer, Milton
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16): : 1451 - 1461
  • [40] Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of blood pressure: the EMPEROR-Preserved trial
    Boehm, Michael
    Butler, J.
    Filippatos, G.
    Ferreira, J. P.
    Pocock, S. J.
    Abdin, A.
    Mahfoud, F.
    Brueckmann, M.
    Saloustros, I.
    Schueler, E.
    Ponikowski, P.
    Wanner, C.
    Zannad, F.
    Packer, M.
    Anker, S. D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 132 - 132
12345